

First Total Synthesis of Optically Active Panaxydol, a Potential Antitumor Agent Isolated from *Panax Ginseng*


Wei Lu, Guangrong Zheng, Haji, A. Aisa, Junchao Cai*

Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 200031, China


Received 24 August 1998; revised 13 October 1998; accepted 19 October 1998

Abstract: The first total synthesis of panaxydol 1 is described, starting from L-(+)-diethyl tartrate 2.
© 1998 Published by Elsevier Science Ltd. All rights reserved.

Panax ginseng C. A. Meyer is one of the most important oriental medicinal plants.¹ The biologically active constituents of ginseng have been pursued extensively, and recently many polyacetylenic compounds, including panaxydol 1, were isolated.² These polyacetylenic compounds have received attention as a possible new type of antitumor agent.³



The absolute configuration⁴ of panaxydol 1 was determined to be (3*R*, 9*R*, 10*S*)-9,10-epoxy-heptadec-1-ene-4,6-diyn-3-ol. Herein, the first total synthesis of optically active panaxydol 1 is described.




Scheme 1: a) Swern oxid. b) $n\text{-C}_6\text{H}_{13}\text{P}^+\text{Ph}_3\text{Br}^-$, $n\text{-BuLi}$, THF, $-78 - 0^\circ\text{C}$., 75% in two steps c) 10%Pd/C, 95%EtOH, 72hr, 85%. d) $p\text{-TsCl}$, Py. 96%. e) $p\text{-TsOH}$, MeOH. f) K_2CO_3 , MeOH, 90% in two steps. g) MOMCl, $i\text{-Pr}_2\text{NEt}$, CH_2Cl_2 , $0^\circ\text{C} - \text{rt}$, 82%. h) $\text{HCCLi}\cdot\text{NH}_2(\text{CH}_2)_2\text{NH}_2$, THF-HMPA, -20°C , 78%. i) MsCl , Et_3N , Py. j) MeOH, $\text{HCl}(\text{cat.})$. k) K_2CO_3 , MeOH, 77% in three steps. l) NBS, AgNO_3 , acetone, 82%.

The absolute configurations of C9 and C10 in panaxydol 1 were established using L-(+)-diethyl tartrate 2 as a chiral template (Scheme 1). Accordingly, 2 was transformed into the monobenzyl ether 3 according to the known procedure.⁵ Swern oxidation of 3, subsequent Wittig reaction with $n\text{-C}_5\text{H}_{11}\text{CH}=\text{PPh}_3$ and catalytic hydrogenation afforded the primary alcohol 4, which on successive treatment with $p\text{-TsCl}$ in

pyridine, acidic methanol and excess K_2CO_3 in methanol gave the epoxy alcohol **5**. The secondary hydroxyl group of **5** was protected as the methoxymethyl (MOM) ether to yield **6**, which was allowed to react with lithium acetylide to give the coupling product **7**. By treatment with methylsulfonyl chloride, methanolic HCl and K_2CO_3 in methanol, **7** was converted into the epoxide **8**, which was reacted with NBS and $AgNO_3$ ⁶ to afford the (9*R*, 10*S*) C6-C17 fragment **9** of panaxydol **1**.

Using the Cadiot-Chodkiewicz reaction,⁸ fragment **9** was then coupled with (3*R*)-(t-butyldiphenylsilyloxy)-pent-1-en-4-yne **10**⁷. After deprotection of the TBDPS group, panaxydol **1** was obtained⁹ (Scheme 2).



Scheme 2: a) $CuCl$, $NH_2OH \cdot HCl$, $EtNH_2$, $MeOH$, $0^\circ C$, 69%. b) TBAF, THF , rt , 66.5%.

In conclusion, panaxydol **1** was obtained in 14 steps in 10.1% overall yield, starting from the monobenzyloxy ether **3** which was prepared from L-(+)-diethyl tartrate **2**.

References and notes:

1. Chang, H.; But, P. P. *Pharmacology and application of Chinese Materia Medica*, Vol I., 1986, P17, World Scientific, Singapore.
2. Poplawski, J.; Wrobel, J. T.; Glinka, T. *Phytochemistry*, **1980**, *19*, 2464.
3. Matsunaga, H.; Mori, M.; Takata, K.; Nakamura, M. *Cancer Chemother. Pharmacol.*, **1994**, *33*, 291.
4. Kobayashi, M.; Mahmud, T.; Umezome, T.; Wang, W.; Murakami, N.; Kitagawa, I. *Tetrahedron*, **1997**, *53*, 15691.
5. a. Feit, P. W. *J. Med. Chem.*, **1964**, *7*, 14.
b. Hungerbuhler, E.; Seebach, D. *Helv. Chim. Acta.*, **1981**, *64*, 687.
6. Nishikawa, T.; Shibuya, S.; Hosokawa, S.; Isobe, M. *Synlett.*, **1994**, 485.
7. Lu, W.; Zheng, G-R.; Cai, J-C. *Synlett* (in press).
8. Grandjean, D.; Pall, P.; Chuche, J. *Tetrahedron Lett.*, **1992**, *33*, 5355.
9. Data for **1**: $[\alpha]_D - 96.1$ ($c = 1.30$, $CHCl_3$); IR(film) 3410 cm^{-1} ; 1H NMR(300MHz, $CDCl_3$) δ_H 0.88 (3H, t, $J=6.7\text{Hz}$), 1.29 (10H, m), 1.50 (2H, m), 2.39 (1H, dd, $J=7.1, 17.7\text{Hz}$), 2.70 (1H, dd, $J=5.5, 17.8\text{Hz}$), 2.94 (1H, m), 3.13 (1H, m), 4.92 (1H, d, $J=5.2\text{Hz}$), 5.27 (1H, dt, $J=1.2, 10.2\text{Hz}$), 5.49 (1H, dt, $J=1.4, 17.0\text{Hz}$), 5.95 (1H, ddd, $J=5.4, 10.1, 17.0\text{Hz}$) ppm; ^{13}C NMR(300MHz, $CDCl_3$) δ_C 136.1, 117.1, 76.7, 75.0, 70.8, 66.3, 63.4, 57.0, 54.3, 31.7, 29.4, 29.1, 27.5, 26.2, 22.6, 19.4, 14.0; HREIMS(m/z) $M^+ - H$ calcd for $C_{17}H_{23}O_2$: 259.1698, found: 259.1704.